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Abstract: Metabolism of anticancer drugs affects their antitumor
effects. This study has investigated the associations of gene expression
of enzymes metabolizing anticancer drugs with therapy response and
survival of breast carcinoma patients.
Gene expression of 13 aldo-keto reductases (AKRs), carbonyl
reductase 1, and 10 cytochromes P450 (CYPs) was assessed using
quantitative real-time polymerase chain reaction in tumors and paired
adjacent nonneoplastic tissues from 68 posttreatment breast carcinoma
patients. Eleven candidate genes were then evaluated in an independent
series of 50 pretreatment patients. Protein expression of the most
significant genes was confirmed by immunoblotting.
AKR1A1 was significantly overexpressed and AKR1C1–4,
KCNAB1, CYP2C19, CYP3A4, and CYP3A5 downregulated in tumors
compared with control nonneoplastic tissues after correction for
multiple testing. Significant association of CYP2B6 transcript levels
in tumors with expression of hormonal receptors was found in the
posttreatment set and replicated in the pretreatment set of patients.
Significantly higher intratumoral levels of AKR1C1, AKR1C2, or
CYP2W1 were found in responders to neoadjuvant chemotherapyuba´cˇkova´, MD, Jir
Pavel Soucˇek, PhD
AKR1C2, AKR7A3, CYP3A4, and carbonyl reductase (CBR1) were
found in tumors and those of AKR1C1, AKR7A3, and CBR1 correlated
with their transcript levels. Small interfering RNA-directed knockdown
of AKR1C2 or vector-mediated upregulation of CYP3A4 in MDA-MB-
231 model cell line had no effect on cell proliferation after paclitaxel
treatment in vitro.
Prognostic and predictive roles of drug-metabolizing enzymes
strikingly differ between posttreatment and pretreatment breast carci-
noma patients. Mechanisms of action of AKR1C2, AKR7A3, CYP2B6,
CYP3A4, and CBR1 should continue to be further followed in breast
carcinoma patients and models.
(Medicine 93(28):e255)
Abbreviations: ADR = adriamycin, AKR = aldo-keto reductase,
CBR = carbonyl reductase, CI = confidence interval, CYP =
cytochrome P450, DFS = disease-free survival, ER = estrogen
receptor, ERBB2 = V-ERB-B2 avian erythroblastic leukemia viral
oncogene homolog 2, FACFDR = false discovery rate, GAPDH =
glyceraldehyde phosphate dehydrogenase, HR = hazard ratio,
KCNAB = shaker-related voltage-gated potassium channel,
subfamily beta, Ki67 = proliferation-related Ki-67 antigen, NACT =
neoadjuvant chemotherapy, NS = not significant, p53 = tumor protein
p53, PCT = paclitaxel, pN = pathological lymph node involvement,
PR = progesterone receptor, pT = pathological tumor size, qPCR =
quantitative real-time polymerase chain reaction, REF = reference
gene, REST = Relative Expression Software Tool, RIN = RNA
integrity number, TRG = target gene.
INTRODUCTION
B reast carcinoma is the most common cancer in womenworldwide.1 The prognosis of breast carcinoma patients
vastly depends on the response of the tumor cells to chemother-
apy. Decreased uptake or eventually increased efflux of drugs,
increased DNA repair or reduced apoptosis, and inactivation of
anticancer drugs by biotransformation enzymes may contribute
to the development of multidrug resistance.2
Phase I biotransformations typically involve substrate
oxidation by the cytochrome P450 (CYP) monooxygenases.
About 20 enzymes from 57 known CYPs are active in metab-
olism of procarcinogens and drugs. Most of them lack important
functional polymorphisms, but CYP2A6, CYP2B6, CYP2C9,
CYP2C19, and CYP2D6 are highly polymorphic suggesting a
potential effect on their expression.3
Cyclophosphamide is a prodrug that must undergo acti-
vation by CYP2C9, CYP2C19, CYP3A4, and CYP3A5.4,5
CYP2B6 also participates in cyclophosphamide activation in
n the response to cyclophosphamide in
t been proven yet.6 CYP2C8, CYP3A4,
r taxane-metabolizing enzymes.7,8 Roles
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of CYP1A2, CYP2A6, and CYP2C8 in 5-fluorouracil formation
from a prodrug tegafur have been described as well.9 CYP2C19
and CYP2D6 polymorphisms have recently been associated
with therapeutic outcome of tamoxifen-treated breast carci-
noma patients.10
CYP2C9, CYP2D6, and CYP3A4 mRNA expression has
unambiguously been detected in mammary gland.11,12 Strong
protein expression of CYP2S1 and CYP3A4 has been associ-
ated with shorter survival time of breast carcinoma patients.13
Despite the knowledge about CYP2W1 substrate specificity is
limited,14 its overexpression in colorectal carcinomas15 raises
interest about future plans for CYP2W1-based cancer therapy.6
Carbonyl reductases (CBRs) and aldo-keto reductases [AKR
andVoltage-gatedKþ channel beta subunit (KCNAB)] are involved
in redox transformations of broad spectrum of carbonyl group-
containing xenobiotics, for example, in the transformation of adria-
mycin to its inactive metabolite adriamycinol.16–18 Mammalian
AKRs are divided into 3 families AKR1, KCNAB, and AKR7 with
13 identified AKR proteins: AKR1A1 (aldehyde reductase),
AKR1B1 and AKR1B10 (aldose reductases), AKR1C1, AKR1C2,
AKR1C3, and AKR1C4 (hydroxysteroid dehydrogenases),
AKR1D1 (D4–3-ketosteroid-5-b-reductase), KCNAB1, KCNAB2,
and KCNAB3 (voltage-gated potassium channels), and AKR7A2
and AKR7A3 (aflatoxin reductases).16
Taken together, available data in the literature suggest a
potential role of drug-metabolizing enzymes in the response of
patients to anticancer therapy. However, studies in target tissues
of patients are limited and therefore urgently needed for trans-
lation of functional data into clinical practice. A comprehensive
set of metabolizing enzymes involved in the chemotherapy
outcome is, thus, still to be defined.
This study explored gene expression levels of drug-meta-
bolizing enzymes in the posttreatment tissues from breast
carcinoma patients treated by neoadjuvant chemotherapy
(NACT). Expression profiles were compared with clinical data
and with response of the patients to NACT in order to identify
putative biomarkers with prognostic and predictive value. Two
cohorts of pretreatment patients were then used for comparison
and assessment of biological relevance of putative biomarkers
on the protein level.
METHODS
Materials
Phenol, chloroform, RNase A, proteinase K, ultrapure
agarose, and other general chemicals were purchased from
Sigma-Aldrich (Prague, Czech Republic). Deoxynucleotides
for polymerase chain reaction (PCR) and molecular weight
standard for electrophoresis (FX174DNA/HaeIII digest) were
products of New England Biolabs, Inc (Ipswich, MA). Taq-
Purple DNA polymerase and Combi PPP Master Mix for PCR
were supplied by Top-Bio s r.o. (Prague). Protein standards for
immunoblotting were kindly provided by Prof Paul F. Hollen-
berg, University of Michigan, Ann Arbor, MI (P450 2B6) and
Prof F. Peter Guengerich, Vanderbilt University, Nashville, TN
(P450 3A4).
Patients
Posttreatment tissue samples of human carcinomas of the
mammary gland were prospectively obtained from 68 incident
Hlava´cˇ et albreast carcinoma patients diagnosed at the Department of
Oncosurgery, Medicon, Prague, during 2006–2010. Patients
were treated by NACT based on 5-fluorouracil/adriamycin/
2 | www.md-journal.comcyclophosphamide or 5-fluorouracil/epirubicin/cyclophospha-
mide and eventually taxanes (for NACT regimens see Table,
Supplemental Digital Content 1, http://links.lww.com/MD/
A124). Paired adjacent tissue samples without morphological
signs of carcinoma (nontumor controls) were available from
43 patients. Collection and pathological processing of tissue
samples and retrieval of data was performed as described
before.19
Pretreatment tissue samples of human carcinomas of the
mammary gland were prospectively obtained from 50 incident
breast carcinoma patients diagnosed at the Faculty Hospital in
Motol, Prague, during 2003–2007. Paired adjacent tissue
samples without morphological signs of carcinoma (nontumor
controls) were available from 31 patients. Patients were treated
by adjuvant chemotherapy and eventually hormonal therapy
after surgery (Table, Supplemental Digital Content 1, http://
links.lww.com/MD/A124). Collection and pathological proces-
sing of tissue samples and retrieval of data was done as
described before20 (Text, Supplemental Digital Content 2,
http://links.lww.com/MD/A124).
For analysis of protein levels of candidate genes, third set
was established. Pretreatment tumor tissue samples of human
carcinomas of the mammary gland were prospectively obtained
from 42 incident histologically verified breast carcinoma
patients diagnosed at the Department of Surgery, Hospital Atlas,
Zlin, during 2012. Collection and handling of tissue samples
and clinical data retrieval adhered to the above-described design
(for study flow diagram, see Figure, Supplemental Digital
Content 3, http://links.lww.com/MD/A124).
The following data on patients were retrieved frommedical
records: age, menopausal status, date of diagnosis, personal and
family history of cancer, tumor size (pT), lymph node (pN) and
distant metastasis (cM), clinical stage, histological type and
grade of tumor, expression of estrogen receptor (ER), progester-
one receptor (PR), V-ERB-B2 avian erythroblastic leukemia
viral oncogene homolog 2 (ERBB2), p53 protein, and Ki-67
protein (for all clinical data, see Table, Supplemental Digital
Content 4, http://links.lww.com/MD/A124).
All patients after the primary chemotherapy and surgery
were followed for local or distant relapse. Response to NACT
was evaluated by Response Evaluation Criteria in Solid Tumors,
as described.21
All patients were asked to read and sign an informed
consent. The study was approved by the Ethical Commission
of the National Institute of Public Health in Prague.
Isolation of Total RNA and cDNA Preparation
Total RNA was isolated from snap frozen tissues using
TRIzol Reagent (Invitrogen, Carlsbad, CA). RNA quantity and
quality (RIN) was assessed and complementary DNA (cDNA)
was synthesized using 0.5mg of total RNA as described
before.20 The cDNA was then preamplified using 25mL of
TaqMan PreAmp Master Mix and a pool of 24 specific
TaqMan Gene Expression Assays (Life Technologies Corp,
Carlsbad; listed in Table, Supplemental Digital Content 5,
http://links.lww.com/MD/A124) according to the published
procedure.19
Quantitative Real-Time PCR
Quantitative real-time PCR (qPCR) was done and results
Medicine  Volume 93, Number 28, December 2014were evaluated as described before.19 Samples from the post-
treatment set were preamplified using TaqMan PreAmp Master
Mix (Life Technologies Corp). cDNA from the pretreatment set
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was used for quantification directly without preamplification
procedure.
The relative standard curve was generated from 5 log
dilutions of 1 nontumor tissue sample (calibrator). Amplifica-
tion efficiencies for each reference gene (REF) and target
gene (TRG) were calculated applying the formula efficiency
¼ 10–1/slope – 1.
EIF2B1, MRPL19, IPO8, and UBB were selected as the
most stable reference genes for data normalization (Text,
Supplemental Digital Content 2, http://links.lww.com/MD/
A124). The qPCR study design adhered to the Minimum
Information for Publication of Quantitative Real-Time PCR
Experiments Guidelines.22
Gene expression and clinical data of the evaluation set
were submitted to Gene Expression Omnibus repository under
accession number GSE56259.
Immunoblotting in Human Breast Carcinoma
Tissues
Tumor tissue samples (n¼ 42) were stored at 808C
before protein isolation. Samples were grinded using a mortar
and pestle and then protein and total RNA was isolated using
Allprep DNA/RNA/Protein Mini kit (Qiagen; Hildesheim,
Germany) according to the manufacturer’s protocol. Total
RNA was then used for qPCR of CYP3A4, CBR1, AKR1C1
(Hs04230636_sH), AKR1C2, and AKR7A3 as described above.
Protein concentration was determined and immunoblotting was
done as previously described.19 Briefly, 20mg of protein was
used for separation by sodium dodecyl sulfate polyacrylamide
gel electrophoresis (10% gel) and transferred onto 0.2mm
Protran nitrocellulose membrane (Whatman; Kent, UK).
Protein standards of CYP2B6, CYP2S1, and CYP3A4 were
used in amount of 0.25–1 pmol of purified protein per lane.
First, membranes were incubated in blocking solution (Clear
Milk Blocking Buffer; Pierce Thermo Scientific, Rockford, IL).
Then, membranes were incubated with primary antibodies
against CYP2B6 (dilution 1:200; Abgent, San Diego, CA),
CYP2S1 (dilution 1mg IgG/mL), CYP3A4 (dilution 5mg
IgG/mL23), AKR1C1 (dilution 1:1000; Aviva Systems Biology,
San Diego), AKR1C2 (dilution 1:100; Aviva Systems Biology),
AKR7A3 (dilution 1:1000; Genetex, Inc, Irvine, CA), CBR1
(dilution 1:1000; Genetex), or glyceraldehyde phosphate dehydro-
genase (GAPDH) (dilution 1:1000; Cell Signaling Technology,
Danvers, MA) overnight at 48C. Membranes were then incubated
2 hours at room temperature with anti-rabbit horseradish-peroxi-
dase-conjugated secondary antibodies (dilution 1:10,000; Sigma
Aldrich, Prague, Czech Republic). Protein bands were visualized
with an Enhanced Chemiluminescence Detection System (Pierce
Biotechnology, Thermo Scientific Pierce Protein Research Pro-
ducts, Rockford, USA) by Carestream Gel Logic 4000 PRO
Imaging System (Carestream Health, New Haven, CT). Densito-
metry was performed using Carestream v5.2 program (Carestream
Health) as previously described.19
Cells and Culture Conditions
Human breast carcinoma MDA-MB-231 cell line (without
expression of hormonal receptors and ERBB2, ie, triple nega-
tive) was purchased from American Type Culture Collection
(Manassas, VA). Cells between passages 4 and 40 were used for
all experiments. Cell line was authenticated and genomic
Medicine  Volume 93, Number 28, December 2014stability monitored in the fourth and 40th passages by short
tandem repeat profiling using PowerPlex ESI 17 Pro System
(Promega Corp, Madison, WI). Cells were cultured in basic
# 2014 Lippincott Williams & Wilkinsmedium with added 10% fetal bovine serum in a humidified
atmosphere of 5% CO2 at 378C. RPMI 1640 containing extra L-
glutamine (300mg/mL), sodium pyruvate (110mg/mL), 15mM
4-(2-Hydroxyethyl)piperazine-1-ethanesulfonic acid buffer,
penicillin (100U/mL), and streptomycin (100mg/mL) was used
as a basic medium. The cells were trypsinized by 0.25% trypsin
and 0.02% Ethylenediaminetetraacetic acid in phosphate-buf-
fered saline (all chemicals from PANBiotech GmbH, Aiden-
bach, Germany).
AKR1C2 siRNA Knockdown
Cells were seeded at 5 104 per well (approximately at 70%
confluence) of a 24-well plate in culture medium without anti-
biotics and cultured overnight. Next day culture medium was
replaced by transfection mix. For knockdown, a sample of the
pools of target small interfering RNA (siRNA) (predesigned,
AKR1C2 siRNA, ID: s3991), or positive control (GAPDH siRNA,
cat. no.: 4390849) or negative control (cat. no.: 4390846) (all
15 nM/well) in Reduced-Serum Minimal Essential Medium
(OPTIMEM) was incubated with Lipofectamine 3000 reagent
(all chemicals from Life Technologies), and added to OPTIMEM-
conditioned cells in a total volume of 250mL. After 24 hours
incubation, an equal volumeof culturemediumwithout antibiotics
with 20% fetal bovine serum was added, resulting in final con-
centrations of 10% fetal bovine serum (500mL/well). Knockdown
efficiencies were determined by qPCR and immunoblotting after
48 hours of growth after addition of culture medium.
Transfection With pcDNA3.1–CYP3A4 Vector
Cells were seeded at 5  104 per well (approximately at
70% confluence) of the 24-well plate in culture medium and
cultured overnight. Next day, culture medium was replaced by
the fresh complete culture medium (500mL) including 50mL of
DNA–lipid complex (0.5mg of plasmid pcDNA 3.1–CYP3A4
or empty plasmid pcDNA 3.1 as negative control; GenScript,
Piscataway, NJ). Cells were transfected by mixing with Lipo-
fectamine 3000 reagent according to the instructions of man-
ufacturer (Life Technologies). After 48 hours of transfection,
cells were washed and supplemented with the fresh culture
medium. Next day, cells were harvested and seeded at approxi-
mately 25% confluence onto 24-well plate in culture medium
with various concentrations (100, 500, and 1000mg/mL) of
Geneticin (Santa Cruz Biotechnology, Dallas, TX) for selection
of geneticin-resistant cells. Selective media were replenished
every 3 days and percentage of surviving cells was monitored.
After 9 days, 500mg/mL of geneticin was selected to maintain
cell line expressing CYP3A4. CYP3A4 expression was mon-
itored by qPCR and immunoblotting.
Cell Proliferation Assessment by Flow Cytometry
Cells were seeded at 1  105 per well of the 24-well plate
and propagated in culture medium. Next day (after 18 hours),
culture medium was replaced by the culture medium without
drugs (control) or with 100 nM paclitaxel (PCT) or 30mM
adriamycin (LC Laboratories, Woburn, MA). Cells were har-
vested after 24 hours and fixed in 70% ethanol at 48C overnight.
Fixed cells were washed with phosphate-buffered saline, incu-
bated with 40mg/mL propidium iodide and 100mg/mL RNase
in phosphate-buffered saline, and cell cycle was analyzed using
flow cytometer FACSVersa (Becton, Dickinson and Company,
Expression of Metabolic Genes in Breast CarcinomaFranklin Lakes, NJ). CYP3A4 and AKR1C2 expression was
monitored by qPCR and immunoblotting in parallel samples
48 hours after exposure to drugs.
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TABLE 1. Differences in Transcript Levels Between Tumor and
Control Tissues of Breast Carcinoma Patients
Gene
Symbol P Value
 Tumor vs
Control
Fold
Change
AKR1A1 <0.001z " 1.55
AKR1B1 NS — 1.13
AKR1B10 0.004 " 3.02
AKR1C1 <0.001z # 0.18
AKR1C2 <0.001z # 0.14
AKR1C3 <0.001z # 0.36
AKR1C4 <0.001z # 0.09
AKR1D1 NS — 1.63
AKR7A2 NS — 1.09
AKR7A3 0.022 " 1.62
CBR1 NS — 0.95
CYP1A2y 0.029 " 3.81
CYP2B6 0.027 " 2.55
CYP2C8 NS — 0.90
CYP2C9 NS — 0.70
CYP2C19y <0.001z # 0.35
CYP2D6y 0.035 " 1.75
CYP2S1y 0.007 " 1.44
CYP2W1 0.045 " 2.46
CYP3A4 <0.001z # 0.19
CYP3A5 <0.001z # 0.27
KCNAB1 <0.001z # 0.32
KCNAB2 0.026 " 1.32
KCNAB3 0.012 " 1.34

Significantly deregulated genes by the REST2009 software (P values
displayed). yn¼ 52 (n¼ 68 for the rest of genes). zResults, which passed
correction for multiple testing (q¼ 0.002). AKR ¼ aldo-keto reductase,
CYP ¼ cytochrome P450, NS, not significant. Results from the posttreat-
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Raw cycle threshold (Ct) data were analyzed by Relative
Expression Software Tool (REST) 2009 program (Qiagen,
Hildesheim, Germany). Each sample was assayed in duplicate
and the mean value was used for calculations. Samples with Ct
>40 were treated as missing data. For statistical analyses of
associations of transcript levels with clinical data nonparametric
tests (Kruskal–Wallis, Mann–Whitney, and Spearman rank)
were used. Tested variables were as follows: menopausal status
(premenopausal vs postmenopausal), tumor size in millimeter
and pT (pT1 vs pT2–4), lymph node metastasis (pN0 vs pN1–
3), histological type (ductal vs other invasive breast carcinoma),
pathological grade (G1 or G2 vs G3), stage (SI vs SII–SIII), ER,
PR, ERBB2, and p53 expression (positive vs negative), Ki-67
expression in percentage of positive tumor cells; and response to
NACT (partial pathological response vs stable disease or pro-
gression). Samples with complete pathological response after
NACT have not been included into the study because of the lack
of tumor tissue. Disease-free survival (DFS) was defined as the
time elapsed between surgical treatment and disease pro-
gression or death from any cause.20 Patients lost to follow-
up (n¼ 5 in the posttreatment set) were excluded from the DFS
analyses. DFSwas evaluated by the Kaplan–Meier method and
the log-rank test was used for evaluation of the compared
groups of patients. For multivariate analysis, the Cox pro-
portional hazards model was used. P values are departures
from 2-sided tests. A P value of <0.05 was considered stat-
istically significant. Statistical analyses were done using SPSS
v16.0 program (SPSS Inc, Chicago, IL). The correction for
false discovery rate (FDR) was applied according to Benjamini
and Hochberg24 and q-values are provided for each com-
parison.
RESULTS
Transcript Levels in Tumors and Nonneoplastic
Control Tissues
AKR1A1, AKR1B10, AKR7A3, KCNAB2, and KCNAB3
were significantly overexpressed in tumors compared with
nonneoplastic control tissues from the posttreatment set. On
the opposite, AKR1C1, AKR1C2, AKR1C3, AKR1C4, and
KCNAB1 were significantly downregulated in tumors.
CYP1A2, CYP2B6, CYP2D6, CYP2S1, and CYP2W1 were
significantly overexpressed whereas CYP2C19, CYP3A4, and
CYP3A5 were significantly downregulated in tumors. No sig-
nificant changes in expression of AKR1B1, AKR1D1,
AKR7A2, CBR1, CYP2C8, and CYP2C9 between tumor and
control tissues were found. Fold change between tumor and
control tissues (mean expression values) with P values calcu-
lated by REST 2009 are listed in Table 1.
Associations of Transcript Levels With Clinical
Data in the Posttreatment Set
Associations of transcript levels of all genes with clinical
data were analyzed, but to retain concise style only significant
results are reported in Table 2. For this purpose, solely gene
expression levels in tumors were evaluated.
Postmenopausal patients had significantly higher
AKR1B10 levels (P¼ 0.026) than the premenopausal patients.
Tumor size negatively correlated with CYP2C8 and CYP2C19
Hlava´cˇ et allevels (Table 2). Patients without lymph node metastasis had
significantly higher intratumoral CYP2C9 levels than patients
with lymph nodes involved (P¼ 0.049). CBR1 levels were
4 | www.md-journal.comsignificantly higher in grade 3 (undifferentiated) tumors than
in grade 1 or 2 (well or moderately differentiated). On the
opposite, AKR7A3, CYP2B6, and CYP2C9 levels were sig-
nificantly higher in grade 1 or 2 tumors compared with grade 3 .
CYP3A5 levels were significantly higher in tumors expressing
ERBB2 than in ERBB2 negative. Conversely, AKR7A3,
CYP2B6, and CYP2C8 levels were significantly higher in
ER expressing tumors than in those without ER expression.
AKR7A3 and CYP2B6 levels were significantly higher in PR
expressing tumors than in those without PR expression.
AKR1C4 and CBR1 levels positively, and AKR7A3 and
CYP2B6 levels negatively, correlated with Ki-67 protein
expression. When correction for multiple testing (Benja-
mini–Hochberg FDR) was applied, only associations between
CYP2B6 levels and grade, and expression of ER, PR, and Ki-67
remained significant (Table 2).
Patients with partial response (responders, n¼ 38) to
NACT had significantly higher intratumoral AKR1C1,
AKR1C2, or CYP2W1 transcript levels than patients with
stable or progressive disease, that is, nonresponders (n¼ 24)
(1.17 0.15 vs. 1.29 0.13, P¼ 0.003; 1.81 0.19 vs
1.96 0.25, P¼ 0.016; and 1.64 0.14 vs 1.72 0.13,
P¼ 0.025; q¼ 0.004 for all; respectively). Three patients solely
treated by hormonal regimens and 2 patients with unknown
response were excluded from this analysis. Patients with
ment set that have been confirmed in pretreatment set of patients are
depicted in bold.intratumoral CYP3A4 or AKR1C2 levels higher than median
had significantly longer DFS than the remaining patients
(n¼ 63, mean DFS: 71.8 vs 61.5 months, P¼ 0.015, DFS:
# 2014 Lippincott Williams & Wilkins
TABLE 2. Significant Associations of Intratumoral Transcript Levels With Clinical Data of Patients in the Posttreatment Set
Gene
Tumor Size,
mmy
Grade

ER Expression

PR Expression

Ki-67
Expressiony1 or 2 3 Positive Negative Positive Negative
AKR1C4 NS NS NS NS r¼ 0.325
P¼ 0.031
AKR7A3 NS 1.09 0.10 1.14 0.11 1.09W 0.11 1.15W 0.09 1.09W 0.11 1.15W 0.09 r¼0.259
P¼ 0.028 PU 0.020 PU 0.032 P¼ 0.034
CBR1 NS 1.10 0.05 1.08 0.05 NS NS r¼ 0.241
P¼ 0.019 P¼ 0.049
CYP2B6 NS 1.22 0.18 1.51 0.21 1.28W 0.21 1.52W 0.22 1.30W 0.22 1.50W 0.24 r¼0.484
P< 0.001z P<0.001z PU 0.002z P< 0.001z
CYP2C8 r¼0.348 NS 1.57W 0.13 1.64W 0.08 NS NS
P¼ 0.005 PU 0.024
CYP2C9 NS 1.41 0.17 1.48 0.11 NS NS NS
P¼ 0.022
CYP2C19 r¼0.284 NS NS NS NS
P¼ 0.046
For statistical analyses, a ratio of Ct for particular target gene (TRG) to arithmetic mean of Ct for all reference genes (TRG/REF) was calculated for each
sample. Therefore, the lower is the TRG/REF ratio, the higher is the TRG transcript level. All clinical data and all genes have been analyzed, but to retain
concise style only significant changes are reported.

P values were calculated by the Mann–Whitney test. MeanSD values are TRG/REF calculated by
the ANOVA test to assess directions of associations. yP and r values were calculated by the Spearman rank test. zResults that passed correction for
ome
nt s
Medicine  Volume 93, Number 28, December 2014 Expression of Metabolic Genes in Breast Carcinoma71.6 vs 60.9 months, P¼ 0.012, respectively; Figure 1). Multi-
variate analysis using the Cox regression hazards model with
pT, pN, grade, and ER as covariates has confirmed these
associations (hazard ratio [HR]¼ 8.79, 95% confidence interval
[CI]¼ 1.09–70.56, and P¼ 0.041 for CYP3A4 and HR¼ 9.82,
95% CI¼ 1.02–94.05, P¼ 0.048 for AKR1C2).
Associations of Transcript Levels With Clinical
Data in the Pretreatment Set
multiple testing (q¼ 0.004). AKR¼ aldo-keto reductase, CYP¼ cytochr
receptor, SD ¼ standard deviation. Results confirmed in the pretreatmeGenes significantly associated with the most important
clinical data as grade, expression of hormonal receptors,
response to NACT or DFS, and genes strongly deregulated
1,0
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0,0
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FIGURE 1. Associations between gene expression levels and DFS of pos
patients (n¼65) divided into 2 groups according to themedian of tran
transcript levels and solid lines represent the groupwith higher levels th
rank test. Gene names and significant differences between groups are d
style only significant changes are reported. DFS ¼ disease-free surviv
# 2014 Lippincott Williams & Wilkinsin tumors (significant after correction for multiple testing) in the
posttreatment set were included into the study of pretreatment
patients. Thus, AKR1A1, AKR1C1, AKR1C2, AKR1C3,
AKR1C4, AKR7A3, KCNAB1, CBR1, CYP2B6, CYP2C8,
CYP2S1, CYP3A4, and CYP3A5 were further followed in this
patient set. As opposed to the posttreatment set no amplification
of cDNA was used in the pretreatment set. CYP2C19 and
CYP2W1 could not be validated in the pretreatment set owing
to gene expression levels below the limit of quantification in
P450, ER¼ estrogen receptor, NS¼ not significant, PR¼ progesterone
et are depicted in bold.samples without preamplification.
As for the posttreatment set, several associations were
found (Table 3). However, after correction for multiple testing,
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ttreatment patients. Kaplan–Meier survival curves were plotted for
script levels in tumors. Dashed lines represent the groupwith lower
anmedian. Differences between groupswere compared using log-
isplayed. All clinical data have been analyzed, but to retain concise
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TABLE 3. Significant Associations of Intratumoral Transcript Levels With Clinical Data of Patients in the Pretreatment Set
Gene
Tumor
Sizey,
mm
Grade

ER Expression

PR Expression

ERBB2

P53 Expression

1 or 2 3 Positive Negative Positive Negative Positive Negative Positive Negative
AKR1C1 r¼0.333 NS NS NS NS NS
P¼ 0.019
AKR1C3 NS NS NS NS 1.18 0.10 1.11 0.07 NS
P ¼ 0.045
AKR7A3 NS NS 1.00W0.11 1.14W0.09 1.01W 0.12 1.08W 0.13 NS 1.12 0.09 1.01 0.12
P < 0.001z PUW0.050 NS P ¼ 0.006
CYP2B6 NS NS 0.98W 0.09 1.28W 0.14 0.99W 0.12 1.18W 0.19 NS 1.22 0.18 1.01 0.13
P < 0.001z P U 0.001z P < 0.001z
CYP2C8 NS NS 1.44W 0.08 1.51W 0.08 NS NS NS
P < 0.026
CYP2S1 r¼0.302 NS NS NS 1.12 0.05 1.08 0.03 NS
P¼ 0.039 P¼ 0.046
CYP3A4 r¼0.314 NS NS NS NS NS
P¼ 0.030
For statistical analyses, a ratio of Ct for a particular target gene (TRG) to arithmetic mean of Ct for all reference genes (TRG/REF) was calculated for each
sample. Therefore, the lower is the TRG/REF ratio, the higher is the TRG transcript level. All clinical data have been analyzed, but to retain concise style only
significant changes are reported.

P values were calculated by the Mann–Whitney test. MeanSD values are TRG/REF calculated by the ANOVA test
to assess directions of associations. yP values and r values were calculated by the Spearman rank test. zResults that passed correction for multiple
testing (q¼ 0.004). Confirmed results from the posttreatment set are depicted in bold. AKR ¼ aldo-keto reductase, ANOVA ¼ analysis of variance,
via
Hlava´cˇ et al Medicine  Volume 93, Number 28, December 2014only associations between AKR7A3 and expression of
ER and those between CYP2B6 and expression of PR, ER,
and p53 remained significant. Association between CYP2B6
and expression of hormonal receptors has also previously
been observed in the posttreatment set (Table 2). Associ-
ations between AKR7A3 or CYP2C8 and expression of ER
were also observed in both sets although they did not
pass correction for multiple testing in one or both sets.
Notable associations between AKR7A3 or CYP2B6 and
expression of p53 protein (P¼ 0.006 and P< 0.001, respect-
ively; Table 2) could not be compared with the posttreat-
ment set because of the lack of data on p53 expression in
this set.
Patients with higher intratumoral AKR7A3 or CYP2B6
levels than median had significantly longer DFS than those with
lower levels (n¼ 50, DFS: 85.3 vs 68.9 months, P¼ 0.032; and
DFS: 93.2 vs 64.1 months, P¼ 0.019, respectively; Figure 2).
Multivariate analysis using the Cox regression hazards model
with pT, pN, grade, and ER as covariates has confirmed
association of high AKR7A3 expression with longer DFS
(HR¼ 3.83, 95% CI¼ 1.03–14.29, and P¼ 0.045), but not that
of CYP2B6 with DFS (P¼ 0.083).
The patients from the pretreatment set were also divided
into subgroups according to therapy type. Adjuvant chemother-
apy-treated patients (n¼ 25) with higher intratumoral AKR7A3
or CBR1 levels than median had significantly longer DFS than
those with lower levels (DFS: 91.1 vs 57.8 months, P¼ 0.040,
and DFS: 89.4 vs 58.1 months, P¼ 0.042, respectively; Figure,
Supplemental Digital Content 6, http://links.lww.com/MD/
A124). Patients treated with hormone (n¼ 23) with higher
intratumoral CYP3A4 or CBR1 levels than median had signifi-
cantly shorter DFS than those with lower levels (DFS: 52.8 vs
CYP¼ cytochrome P450, ER¼ estrogen receptor, ERBB¼V-ERB-B2 a
PR ¼ progesterone receptor, SD ¼ standard deviation.90.4 months, P¼ 0.007, and DFS: all patients with high CBR1
censored, P¼ 0.004, respectively; Figure, Supplemental Digital
Content 6, http://links.lww.com/MD/A124). Because of the low
6 | www.md-journal.comnumbers of patients in the compared groups, multivariate
analysis was not done and the observed trends have to be
interpreted with caution.
Transcript levels of CYP2B6 (P< 0.001), CYP3A4
(P< 0.001), AKR1C1 (P< 0.022) AKR1C2 (P< 0.001), and
AKR7A3 (P¼ 0.001) were significantly lower in posttreatment
tumors compared with the pretreatment ones.
Protein Expression of AKR1C1, AKR1C2, AKR7A3,
CYP2B6, CYP2S1, CYP3A4, and CBR1 in Breast
Tumors
Putative markers for which transcript levels significantly
associated with response to NACT or DFS of the patients were
evaluated at the protein level. Expression of AKR1C1,
AKR1C2, AKR7A3, CYP3A4, and CBR1 was assessed by
immunoblotting in protein lysates from tumor tissue samples
of the independent pretreatment set of patients. No protein of the
anticipated size corresponding to CYP2B6 or CYP2S1 was
detected in the tumor tissues by the commercially available
(CYP2B6) or homemade (CYP2S1) antibodies. CYP2B6 and
CYP2S1 protein standards were correctly and quite specifically
detected by these antibodies using protein standards and human
liver microsomes (Figure, Supplemental Digital Content 7,
http://links.lww.com/MD/A124). However, we did not observe
protein band comigrating with the standard in all inspected
tumors. We regularly detected 2 protein bands with molecular
weight by approximately 10–15 kg/mol higher than CYP2B6
there. Bands with different molecular weight than the CYP2S1
standard have also been detected in tumors (Figure, Supple-
mental Digital Content 8, http://links.lww.com/MD/A124).
The remaining proteins were well detected and quantified
n erythroblastic leukemia viral oncogene homolog 2, NS, not significant,by densitometry. GAPDH expression was used as an internal
control for normalization of the results. Purified protein stan-
dards (CYP2B6, CYP2S1, and CYP3A4), MT-3 cells lysate
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pool of tumor samples (AKR7A3) were used as a calibrator
for comparison of variability among membranes. Analysis
revealed high interindividual variability in expression of all
examined proteins (Figure 3). Protein levels of AKR1C1,
AKR7A3, and CBR1 significantly correlated with the respect-
ive transcript levels assessed by qPCR in the same tumor
samples (Spearman r¼ 0.47, P¼ 0.003, Spearman r¼ 0.61,
P< 0.001, and Spearman r ¼ 0.44, P¼ 0.007, respectively)
(Figure 4). The protein levels of CYP3A4 and AKR1C2 did not
significantly correlate with the respective transcript levels
(P> 0.05). Three bands recognized by anti-AKR1C2 anti-
bodies in the anticipatedmolecular weight rangewere analyzed
by densitometry both separately (not shown) and together
(Figure 3) with comparable results, that is, lack of correlation
with the transcript level.
Functional Aspects
AKR1C2 and CYP3A4 were studied in more detail using
breast carcinoma model MDA-MB-231 (triple negative) cell
line in vitro. In the first experiment, interactions between
CYP3A4, AKR1C1, and PCT or adriamycin were addressed.
Treatment of the cells with 100 nM PCT resulted in induction of
CYP3A4 transcript level, but had no effect on its protein level.
AKR1C2 transcript was unaffected, but its protein level was
decreased by both 100 nM PCT and 30mM adriamycin. Adria-
mycin had no effect on transcript or protein level of CYP3A4
(Figure 5).
siRNA-directed knockdown of AKR1C2 expression
or pcDNA3.1-CYP3A4 plasmid-mediated upregulation of
CYP3A4 expression had no effect on proliferation of MDA-
MB-231 cells treated by 100 nM PCT (Figure 6). No effect of
30mM adriamycin on the MDA-MB-231 proliferation was
observed using flow cytometry (results not shown).
lower transcript levels and solid lines represent the group with hig
using log-rank test. Gene names and significant differences betwe
retain concise style only significant changes are reported. DFS ¼DISCUSSION
Identification of biomarkers with prognostic and predictive
value in terms of survival of patients and their response to
# 2014 Lippincott Williams & Wilkinschemotherapy is a prerequisite step for individualization of
cancer treatment.
We studied gene expression of 24 genes coding principal
anticancer drug-metabolizing enzymes in tissues from breast
carcinoma patients treated by NACT. Our goal was to discover
new putative biomarkers with prognostic and predictive value
and compare the importance of these biomarkers in 2 groups of
patients with different prognoses. In the first phase of analyses,
we have identified a number of promising candidates. These
candidates were further studied in the set of pretreatment
samples and finally protein levels were followed in the third
set of samples.
From our observations, we can generalize that the extent of
deregulation of gene expression of drug-metabolizing enzymes
in tumors of breast carcinoma patients does not strikingly differ
between posttreatment and pretreatment patients. However,
vast differences between both sets in associations of intra-
tumoral gene expression levels with clinical data of patients
observed by this study suggest different prognostic and even-
tually predictive roles of these particular enzymes.
Taking into consideration the issue of multiple testing, just
overexpression of CYP2B6 in tumors expressing hormonal
receptors compared with those without such expression is the
only universal association typical for both sets. Overexpression
of CYP2B6mRNA in ER-positive breast tumors compared with
the normal breast tissue or ER-negative tumors has previously
been observed,25,26 and therefore, our study validates these
results on independent sets of patients. We have observed
the association of high CYP2B6 mRNA expression with longer
DFS of the pretreatment patients for the first time. Although it
has previously been shown that ERs regulate CYP2B6 expres-
sion in vitro through direct binding to an estrogen responsive
element located in the CYP2B6 promoter,27 we have not
detected a protein product of the anticipated molecular weight
in breast tumors. Thus, we confirmed the lack of CYP2B6
protein in breast tumors reported by others.28 In contrast to the
levels than median. Differences between groups were compared
groups are displayed. All clinical data have been analyzed, but to
ase-free survival.published data, we revealed bands of higher molecular weight
than the protein standard in all tested samples. The issue of
inadequate quality of antibodies is diminished by the fact that
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FIGURE 3. Protein expression of selected candidates in tumors of breast carcinoma patients. Protein expression of (A) AKR1C1,
(B) AKR1C2, (C) AKR7A3, (D) CYP3A4, and (E) CBR1 was assessed by immunoblotting (left part) and evaluated by densitometry with
normalization to GAPDH (right part) in representative set of breast tumors as described in the ‘‘Methods.’’ Anticipated molecular weight
in
Hlava´cˇ et al Medicine  Volume 93, Number 28, December 2014the CYP2B6 protein standard was well recognized and the
specificity of antibodies was also good. The nature of the
protein bands recognized by anti-CYP2B6 antibodies in breast
tumors is being studied.
Associations between expression of hormonal receptors
and AKR7A3 were observed although they have not passed
correction for multiple testing in both sets. Our data support
the higher AKR7A3 protein expression in samples from ER-
positive breast carcinoma patients as reported previously.29 In
concordance with the hormonal receptor expression being a
factor of more favorable prognosis,30 high intratumoral
AKR7A3 expression was associated with longer DFS of pre-
(MW) in kg/mol (in the 20% range) is presented for each prote
GAPDH ¼ glyceraldehyde phosphate dehydrogenase.treatment patients in both univariate and multivariate analyses.
AKR7A3 protein expression was found in breast tumors for the
first time and its high correlation with mRNA levels (P< 0.001)
8 | www.md-journal.comdemonstrates the biological relevance of AKR7A3 for breast
carcinoma. As no other data about the role of AKR7A3 in the
prognosis of breast carcinoma patients exist, validation of our
findings will be subject of independent follow-up studies.
From other associations found, three may particularly
attract further attention. First, responders to NACT had higher
intratumoral level of AKR1C2 compared with nonresponders
and this association was confirmed by the observed longer DFS
in patients with high AKR1C2 level. The association of
AKR1C2with DFSwas not observed in the pretreatment patient
set suggesting that it may be specific for patients receiving
chemotherapy. The present study confirmed the previously
according to Human Protein Atlas (http://www.proteinatlas.org).observed downregulation of AKR1C2 (and 1C1 and 1C3) in
breast tumors compared with nonneoplastic tissues.31,32 Our
study, however, does not comply with the previously published
# 2014 Lippincott Williams & Wilkins
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FIGURE 5. Interaction between PCT or doxorubicin and protein
and transcript levels of CYP3A4 and AKR1C2 in vitro. MDA-MB-
231 cell line was incubated without (control) or with 100nM PCT
or 30mM adriamycin (ADR) as described in the ‘‘Methods.’’ qPCR
and immunoblotting were done 48h after the incubation. Ct
values from qPCR are presented in the upper part. The higher
is the Ct value the lower is the transcript expression. Immunoblots
with 10mg of protein per lane for AKR1C2 and 20mg of protein or
0.25 pmol of standard for CYP3A4 per lane are presented in the
lower part. Two independent experiments were performed with
consistent results. Ct ¼ cycle threshold, PCT ¼ paclitaxel, qPCR ¼
quantitative real-time polymerase chain reaction.
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# 2014 Lippincott Williams & Wilkinsdata showing that AKR1C2 inhibition by 5b-cholanic acid
restored sensitivity of adriamycin-resistant human breast ade-
nocarcinoma cell line breast tumor cells in vitro.33 We detected
AKR1C2 protein in breast carcinomas underlining a potentially
functional role of AKR1C2 there. The lack of correlation
between AKR1C2 (and CYP3A4) transcript and protein levels
observed in the present study may be explained by the use of
different normalization controls for qPCR and immunoblotting.
The issue of normalization of immunoblotting is a matter of
intensive debate.34 The influence of posttranscriptional proces-
sing and protein stability cannot be ignored as well.
In vitro experiments have shown that PCT and adria-
mycin reduced AKR1C2 protein expression. However,
siRNA-directed knockdown of AKR1C2 had no effect on
the proliferation of cells treated by PCT. Taken together, the
mechanism of action of AKR1C2 in responders to NACT
does not seem to be a result of interactions between AKR1C2
and major drugs used in the breast carcinoma treatment
regimens.
Second, patients with high intratumoral CYP3A4 level had
significantly longer DFS in the posttreatment set. High
CYP3A4 transcript35 or protein36 levels are predictive for poor
response of breast carcinoma patients to docetaxel, which is
inactivated by the enzyme. In contrast, CYP3A4 is known as a
cyclophosphamide5-activating enzyme and from this point of
view, the association of high CYP3A4 level with better DFS
makes sense in the cyclophosphamide-treated patients (n¼ 61
in our posttreatment set). In concert with others,13,28,37 we also
found a striking interindividual variability in intratumoral
vels were analyzed by densitometry with normalization to GAPDH
e genes (Y-axis). Normalized protein and transcript levels were
yde phosphate dehydrogenase.CYP3A4 protein expression among patients. High CYP3A4
protein expression was previously associated with poor sur-
vival of breast carcinoma patients.13 CYP3A4 protein level
www.md-journal.com | 9
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Hlava´cˇ et al Medicine  Volume 93, Number 28, December 2014negatively correlated with the transcript levels in our study,
which could explain the observed discrepancy of our results
with the published data on the prognostic role of CYP3A4.
However, this correlation was insignificant (P¼ 0.117) and
therefore the observed association between CYP3A4 and
DFS must be cautiously interpreted.
PCT transcriptionally activated CYP3A4, but no induction
of P450 3A4 protein was detected in vitro by this study. Thus,
the functional relevance of such interaction is quite low if any.
Adriamycin had no influence on gene or protein expression of
CYP3A4 in vitro. Treatment of cells with enhanced CYP3A4
expression by PCT had no effect on the cell proliferation.
However, we were able to induce CYP3A4 transcript level
to a high extent, but the protein level was poorly induced in the
MDA-MB-231 cell line. CYP3A4 is a subject to ubiquitin-
dependent proteasomal degradation by the 26S proteasome, a
process involving phosphorylation, ubiquitination, and extrac-
tion of endoplasmatic reticulum membrane into the cytosol.38
Little is known about the nature of these processes in stable
for 24h and then cell proliferation was analyzed using flow cytome
consistent results. PCT ¼ paclitaxel, siRNA ¼ small interfering RNcancer cell models as MDA-MB-231. Therefore, for definite
answer about the mechanism, in vivo models as mice xeno-
grafted with human tumors should be used.
10 | www.md-journal.comThird, a kind of double-facetted effect was observed for
CBR1 in the pretreatment set of patients. A high intratumoral
CBR1 level in a chemotherapy-treated subgroup of patients
associated with longer DFS, but an opposite effect was found
in the hormonal therapy-treated subgroup. These associations
have been observed on quite small groups of patients and thus
need proper validation in larger cohorts of patients. CBR1
inactivates anthracyclines to the respective alcohols impli-
cated in their cardiotoxicity.17,39 Besides the fact that CBR1
genetic polymorphisms have been shown to influence clear-
ance and exposure levels of adriamycin in breast carcinoma
patients,40 just one small study observed no significant
difference in CBR1 activity between tumor and normal
tissues of breast carcinoma patients.41 Results of the present
study support the recently revealed prognostic significance of
decreased CBR1 protein expression (an independent prog-
nostic factor for progression-free and overall survival in
multivariate analyses) in endometrial carcinomas.42 The same
authors previously revealed that suppression of CBR1 expres-
(lower part). Two independent experiments were performed withsion stimulated cancer cell invasion accompanied with the
decrease in E-cadherin expression in uterine cervical squa-
mous cell carcinomas.43 We have no explanation for the
# 2014 Lippincott Williams & Wilkins
reversed effect observed in patients treated solely by the
hormonal therapy.
We detected CBR1 protein level in all followed tumors and
noticed a significant correlation between transcript and protein
level. Thus, CBR1 presents another candidate for functional
verification in breast carcinoma models.
Additionally, posttreatment patients with high intratu-
moral CYP2W1 transcript levels responded better to NACT
than those with low levels. However, we were unable to validate
our results on the nonpreamplified transcript or intratumoral
protein levels because of the very low CYP2W1 expression in
tumor tissues of the pretreatment set of patients. Thus, CYP2W1
remains an independent biomarker for stages II and III color-
ectal carcinoma patients,15 but not for breast carcinoma. Also,
the association between AKR1C1 and response to NACT in the
posttreatment set could not be verified on the pretreatment set of
patients or on the protein level.
CONCLUSIONS
Associations of AKR1C2, AKR7A3, and CBR1 with
prognosis of breast carcinoma patients revealed by this study
should be further followed in independent validation and func-
tional studies. The ambiguous roles of CYP2B6 and CYP3A4
noted by this study warrant investigations focused on regulation
of their expression and posttranscriptional processing specifi-
cally in breast carcinomas.
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